Disclosures

Share This Page

Executive Editors

  • Howard Sandler, MD
    Ronald H. Bloom Chair in Cancer Therapeutics Professor and Chair, Department of Radiation Oncology Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
    Disclosure: In the past two years, Dr. Sandler served as a consultant/advisor for Millennium, Ortho Biotech, Genentech, Varian, Calypso Medical and Takeda, and received honoraria from Sanofi-Aventis and AstraZeneca.
  • Robert Sticca, MD
    Chairman, Program Director and Professor University of North Dakota School of Medicine and Health Sciences

Specialty Editors

  • Maha Hussain, MD, FACP (Bladder Cancer Editor)
    Professor of Medicine and Urology Associate Director for Clinical Research and Co-Leader, Prostate Cancer Program University of Michigan Comprehensive Cancer Center
    Disclosure: In the past two years, Dr. Hussain has served as a consultant/advisor for Lilly, Exelixis and Genmab.
  • Susan Chang, MD (Brain Cancer Editor)
    Professor in Residence and Vice Chair of Neurological Surgery Director, Division of Neuro-Oncology, University of California, San Francisco
    Disclosure: In the past two years, Dr. Chang received research funding from Schering-Plough, NeoPharm and Novartis.
  • Lori J. Goldstein, MD (Breast Cancer Editor)
    Director, The Naomi and Phil Lippincott Breast Evaluation Center Co-Leader, Breast Cancer Clinical Research Program Fox Chase Cancer Center
    Disclosure: In the past two years, Dr. Goldstein served as a consultant/advisor for Roche, Sanofi-Aventis, Amgen, Genentech, Lilly, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Berlex, Pharmion, Eisai and AstraZeneca; received honoraria from Novartis and Bristol-Myers Squibb; and received research funding from GlaxoSmithKline, Merck, Johnson & Johnson, Wyeth, Sanofi-Aventis, Genomic Health, AstraZeneca and Bristol-Myers Squibb.
  • Carolyn Runowicz, MD (Cervical and Ovarian Cancers Editor)
    Associate Dean of Women's Affairs Professor, Department of Obstetrics and Gynecology, Florida International University
    Disclosure: In the past two years, Dr. Runowicz served as a consultant/advisor for Correlogic, Pfizer, Telik, Ikonisys, Bayer and Champions Oncology, Inc.; received honoraria from Champions Oncology, Inc.; and received research funding from ACS and CT DPH.
  • Jennifer Obel, MD (Colorectal Cancer Editor)
    Medical Oncologist, NorthShore University Health System Assistant Clinical Professor of Medicine, University of Chicago
    Disclosure: In the past two years, Dr. Obel served as a consultant/advisor for Onyx.
  • David H. Ilson, MD, PhD (Gastric Cancer Editor)
    Attending Physician, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center Attending Physician and Member, Memorial Hospital Professor of Medicine, Weill Cornell Medical College
    Disclosure: In the past two years, Dr. Ilson received research funding from Pfizer, Sanofi, Genentech, Bristol-Myers Squibb, Bayer, Roche and Bayer/Onyx.
  • Everett E. Vokes, MD (Head and Neck Cancer Editor)
    John E. Ultmann Professor of Medicine and Radiation Oncology Physician-in-Chief, University of Chicago Medicine and Biological Sciences Chair, Department of Medicine, University of Chicago
    Disclosure
    : In the past two years, Dr. Vokes received honoraria from Poniard Pharmaceuticals, Astra-Zeneca, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, ImClone Systems, Amgen, Genentech, Sanofi-Aventis, EMD Serono, Clovis Oncology, Poniard Pharmaceuticals, Celgene, VeriStrat, Pfizer and Agennix; and received research funding from Bristol-Myers Squibb, Genentech, NCI and ASCO TRP.
  • Brian Rini, MD (Kidney Cancer Editor)
    Associate Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Associate Director for Clinical Research at the Cleveland Clinic Taussig Cancer Institute
    Disclosure: In the past two years, Dr. Rini served as a consultant/advisor for Pfizer, Bayer, Genentech, Wyeth, Novartis, AVEO and GlaxoSmithKline, and received research funding from Genentech, Bayer, Pfizer and Wyeth.
  • Edward Agura, MD (Leukemia Editor)
    Director, Hematopoietic Stem Cell Program, Baylor University Medical Center
  • Ghassan K. Abou-Alfa, MD (Liver Cancer Editor)
    Medical Oncologist, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center
    Disclosure: In the past two years, Dr. Abou-Alfa served as a consultant for Abbott, Amgen, Arqule, BMS, Bayer, Celsion, Chugai, Clovis, Daiichi, Exelixis, Genentech, GenVec, Halozyme, ImClone, Jennerex, Medigene, Merck, Momenta, Novartis, OSI, Piramal, Polaris, Proacta, Roche, Sanofi-Aventis, Ziopharm and Vicus. He received research funding from Abbott, Agensys, Amgen, Astella, AstraZeneca, Bayer, Chugai, Genentech, ImClone, Medigene, Momento, Novartis, Polaris, Roche and Sanofi-Aventis.
  • Sonali Smith, MD (Lymphoma Editor)
    Associate Professor of Medicine, University of Chicago Medical Center
    Disclosure: In the past two years, Dr. Smith served as a consultant/advisor for GENIE program, Lilly, Celgene, Spectrum Pharmaceuticals, Biogen Idec, Genentech, GlaxoSmithKline and Cephalon, and received honoraria from Biogen Idec, Genentech and Celgene.
  • Lee Krug, MD (Lung Cancer Editor)
    Associate Attending Physician, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center
    Disclosure: In the past two years, Dr. Krug served as a consultant/advisor for GlaxoSmithKline, Nektar, Amgen, Baxter International, Johnson & Johnson and Poniard Pharmaceuticals, and received research funding from Lilly, Merck, Sunesis Pharmaceuticals, Innovive, CanBas and Novartis.
  • Jeffrey Gershenwald, MD (Melanoma Editor)
    Professor, Department of Surgical Oncology, Division of Surgery, M.D. Anderson Cancer Center
    Disclosure: In the past two years, Dr. Gershenwald served as a consultant/advisor for GlaxoSmithKline.
  • Andrew Ko, MD (Pancreatic Cancer Editor)
    Associate Professor of Clinical Medicine, Division of Hematology/Oncology, UCSF Comprehensive Cancer Center
    Disclosure: In the past two years, Dr. Ko received honoraria from Roche, and received research funding from Abraxis Bioscience (now Celgene), Eli Lilly/ImClone Systems, Genentech, PharmaEngine, ACT Biotech, Wyeth (now Pfizer) and Infinity Pharmaceuticals.
  • Lisa Diller, MD (Pediatric Cancer Editor)
    Clinical Director of Pediatric Oncology, Dana-Farber Cancer Institute/Children's Hospital Associate Professor of Pediatrics, Harvard Medical School
  • Derek Raghavan, MD (Prostate Cancer Editor)
    President, Levine Cancer Institute, Carolinas HealthCare System
    Disclosure: In the past two years, Dr. Raghavan served as a consultant/advisor for ISIS, Schering-Plough, Gerson Lehrman Group, YM BioSciences, Revolution Health Care and Sanofi-Aventis; received honoraria from Biogen Idec; received research funding from Lilly, NCI and Abraxis BioScience; and provided expert testimony for Gerson Lehrman Group.
  • Bruce Roth, MD (Testicular Cancer Editor)
    Professor of Medicine, Washington University School of Medicine in St. Louis
  • Lidia Schapira, MD (Quality of Life Editor)
    Assistant Professor, Department of Medicine, Harvard Medical School Assistant Professor, Medicine, Massachusetts General Hospital
    Disclosure: In the past two years, Dr. Schapira served as a consultant/advisor for EMD Serono.

*** More information about ASCO's conflict of interest policy is available at asco.org.